Duncan Cameron

Chief Financial Officer

T: 0116 238 8200
M: 07753 353 424

Duncan is Catapult’s CFO and directly manages a number of portfolio companies, as well as serving on Catapult's Investment Committees. He has nearly 25 years’ experience within the private equity industry since joining NatWest’s venture capital business in 1989. Duncan has experience of making, managing and realising investments across industry sectors including automotive design, transportation, professional services, software, renewable energy and telecoms.

Following a period spent leading a research and origination team within NatWest’s London office, Duncan relocated to Nottingham in 1996 to help launch a NatWest fund focussed on small / mid-market transactions where he had responsibility for investment across the Midlands.  Following a decision in 2002 by NatWest to focus on larger transactions, Duncan spent a number of years working as a non-executive director and consultant, mainly supporting institutionally backed companies. This period also included work with The Salvation Army on a sustainable income generation fund which saw Duncan involved in evaluating projects in a number of countries including Latvia, Bangladesh and Paraguay.   

Duncan’s first involvement with Catapult came in early 2007 when he was asked to chair the investment committee of the new Catapult Growth Fund.  Later that year he took on an executive role with the business, managing a number of investments and also fulfilling the FD and Deputy MD roles.

Duncan is a Chartered Accountant (ICAS) and holds a B.A. in Business and Administration from Strathclyde University. 

Professor Rob Carroll


T: 0116 238 8200
M: 07976 226 252

Rob is a Director of Catapult Ventures and chairs Catapult’s Investment Committees. Prior to September 2013, Rob was Managing Director of Catapult, which he started in October 1999. He previously worked at 3i plc in Leicester and London and ECI in the Midlands.

Rob is Non-Executive Chairman and Investor in Replay Group, Conduiit and Passport 365. He is also a non-executive director and investor in Open Go Sim and an investor in Ekkosense Ltd.  He has lectured at Nottingham University Business School since 2011 in Venture Capital and Private Equity and was appointed Honorary Professor in August 2013 and Professor of Practice in July 2016. He is also a Mentor and Teacher for the Royal Academy of Engineering Leaders in Innovation Fellowship Programme.

Rob is an honours graduate with an Upper Second-Class Honours degree in Pharmacy from Kings College, London.  He holds an MBA from Bradford University Management School. He also holds an NLP practitioner qualification from the International NLP Trainers Association.

Sarah Cooper

Office Manager 

Tel: 0116 238 8200


Sarah Cooper is the Office Manager based at Catapult's Head Office. Sarah joined Catapult in January 2006 having previously worked for an actuarial firm for eight years and eight years in Ernst & Young's Corporate Finance Department in Birmingham. In addition to general administration, Sarah assists the Group Financial Controller.

Dr Tony Flinn

Venture Partner
GM&C Life Sciences Fund

Tony is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he helps assess service company (CRO) investment opportunities and works with the Fund’s smaller investments to help companies successfully grow.

Tony is a well-known non-executive director and motivational speaker who co-founded Onyx Scientific in 2000 to offer contract chemistry services to many of the world’s leading drug developers. He grew the business to become one the fastest growing technology companies in the UK, employing more than 60 staff at its peak, managed an MBO in 2007, and ultimately sold the business to IPCA, a large Indian pharmaceutical service provider, in 2011.

Tony began his career as a Post-Doctoral Research Fellow, first with the Cancer Research Institute, and then with Oxford University. After a period as a Research Chemist with Dow Chemical he began the first of several business development roles.   

Tony holds a First Class BSc in Chemistry and PhD in Synthetic Organic Chemistry, both from Heriot-Watt University. He is a Fellow of the Royal Society of Chemistry and a Chartered Chemist (FRSC CChem).

Anne Freeman

PA to Chairman

Tel: 0116 238 8200


Anne Freeman is part time PA to Laurence Vaughan and is based at Catapult's offices at Narborough Wood Park, Enderby, Leicester.  She has many years' experience in office administration and has worked with Laurence since 1997.

Hamish Graham


Hamish first joined Catapult in June 2015 as an MBA Summer Intern, and since completing his MBA has built an active portfolio of consulting and business interests.

In addition to serving as an Advisor for Catapult, he is the London Manager for the Pfizer Healthcare Innovation Hub (a digital health accelerator), a business consultant, a surgeon and is one of the Trackside Doctors at Brands Hatch Motor Circuit.

He is a member of the Royal College of Surgeons England with many year’s clinical experience and holds degrees in Medicine (University of Sheffield), Healthcare Ethics & Law (University of Manchester). He has worked in a variety of settings from Somalia to Sheffield both in hospital and pre-hospital settings. He Co-Chaired the Junior Doctors leadership group at Guy’s & St. Thomas’ hospitals, London, and has had broad engagement with Quality Improvement projects at district general hospitals and major trauma centres.

He holds an MBA is from Manchester Business School, where he focussed on Venture Capital and Private Equity.

Kevin D'Silva

Venture Partner - Medical Devices
GM&C Life Sciences Fund

Kevin is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he assesses investment opportunities and works with the Fund’s smaller investments to help companies successfully grow, with a particular focus on medical devices.

Kevin has held a number of non-executive and Chairman positions, including Monica Healthcare, which generated a 3.5x cash return for Catapult, and Crystallon, which generated a 5.2x cash return. He is also a Director and former Chairman of both Surface Transforms plc (AIM listed) and Hallmarq Veterinary Imaging Ltd.

Kevin was a founding director of Ferraris Group plc (FTSE: listed) and created Salusinvest in 2006 to invest in a number of EU and US life science businesses. He is also a former Director of Acuity VCT 3 and Octopus VCT 1. 

Kevin graduated from Leeds University with a BSc in Chemical Engineering and has an MBA from Manchester Business School.


Dr Gareth King


Life Science Partner
GM&C Life Sciences Fund

T: 01625 344300

M: 07720 051988

E: gareth@catapult-ventures.com

Gareth is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, where he has been leading and managing investments since the Fund launched in late 2015.

Prior to joining Catapult, Gareth was CEO of Critical Pharmaceuticals, a clinical stage biotechnology company utilising a proprietary drug delivery technology to develop a pipeline of unique biological drug products, which raised >£4m from investors including Catapult Ventures and the Welcome Trust. Gareth was previously VP Business Development at Pharmaceutical Profiles, which he joined from Manchester-based start-up Cyprotex, where he was Commercial Director.

Gareth began his career in Boston, USA as a Research Fellow at Harvard Medical School. He moved back to the UK and was based at Alderley Park for over 3 years as Bioinformatics Project Manager with AstraZeneca, before joining California-based genomics company Incyte.

Gareth holds an BSc in Microbiology from Sheffield University and a PhD in Molecular Genetics from Edinburgh University.

Corinne Lawrence

Group Financial Controller

Tel: 0116 238 8200


Corinne Lawrence is Group Financial Controller of Catapult Ventures and works across all Catapult funds. She joined the company in January 2002. Prior to this, Corinne worked for seven years as a Portfolio Executive at 3i plc, in Leicester and Nottingham.

Corinne previously worked in audit, specialising in regulated clients and qualified as a Chartered Accountant in 1993.

Natalie Melvin

Portfolio Assistant / Marketing Executive

Tel  0116 238 8200


Natalie has responsibilty for portfolio and compliance administration and marketing activity across all funds.  Natalie first joined Catapult at inception in January 2002 and subsequently returned to the company in 2012 after a career break.

Natalie worked as a Portfolio Assistant and Executive Secretary at 3i plc and has been involved in venture capital administration since 1998. 

Previously Natalie worked as an Executive Secretary in the health service and the newspaper industry.

Natalie holds a BA Hons degree in Italian from the University of Hull.

Laurence Vaughan


T: 0116 238 8200


Laurence has been Chairman of Catapult Ventures since September 2013.

He began his career with PwC in audit and consultancy.  In 1993 he joined Sytner where, as CEO, he led the team that grew the company from a single BMW dealership in Nottingham to a luxury car group with around £1bn revenues by 1997 when it listed on the London Stock Exchange.  Sytner was bought by US-based Penske Group in 2002 and Laurence joined the main Board before becoming Sytner’s Non-Executive Chairman.  Today Sytner has more than 140 prestige dealerships around the UK, including Audi, Bentley, Ferrari, Lamborghini, Land Rover, Lexus, Maserati, McLaren, Porsche and Rolls-Royce.  It has revenues in excess of £5bn and is the UK’s largest automotive retailer.

In 2006 Laurence was appointed Chairman of Alchemy-backed Civica plc, which he helped float on AIM.  He stepped down in 2008 following Civica’s acquisition by 3i plc.  He is also Non-Executive Chairman of The Superbike Factory Ltd, a Livingbridge investment and AD Williams, a British Growth Fund investment.  He has also been Chairman of Idox plc and Anglian Home Improvements.

Laurence is a graduate of Durham University and a Chartered Accountant.

Vijay Curthan

Investment Director
GM&C Life Sciences Fund

T: 01625 344300

M: 07538 942423

E: vijayc@catapult-ventures.com

Vijay is an Investment Director with Catapult’s GM&C Life Sciences Fund. He joined Catapult Ventures in January 2020 and is responsible for leading and managing investments.

He has 12 years’ experience working in private equity, having previously been an investment banker and a pharma industry executive. Vijay is also a Director of Moor Park House care home, a specialist healthcare and rehabilitation facility caring for people with complex needs.

Vijay started his career at Schroders on their graduate training program before working for Citigroup in London and New York. He then joined GlaxoSmithKline as an internal strategy consultant, before moving to the healthcare corporate finance team at Deloitte, where he was an Assistant Director. After a stint with EmiratesNBD in Dubai, he then moved to Muscat to work for the State General Reserve Fund, the sovereign wealth fund of Oman. Thereafter, he was a Vice-President at the Investment Corporation of Dubai, a UAE sovereign wealth fund, where he was part of the team that managed over $10bn of assets. Most recently, he was based in Mauritius and led a $400m private equity fund focused on healthcare investments across sub-Saharan Africa.

Vijay graduated from Cambridge University with a BA in Natural Sciences and Economics and also holds an LLB from the University of London.

Dr David Whitcombe

Venture Partner
GM&C Life Sciences Fund

David is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he assesses investment opportunities and works with the Fund’s smaller investments to help companies successfully grow.

David is a well-known consultant and non-executive director/Chairman who co-founded DxS Diagnostics in 2000 to exploit a personalised medicine technology he had invented while with AstraZeneca Diagnostics. DxS was sold to Qiagen in September 2009 for in excess of £100m. Prior to DxS, David was Head of Technology Development at AstraZenica Diagnostics for four years where he led a team of up to 15 scientists working on new genome technologies.

David began his career as a Post-Doctoral Fellow with Warwick University Department of Biological Sciences, before joining Cambridge University Department of Medicine as a Senior Post-Doctoral Fellow where he researched the Genetics of Human Disease for six years.

David holds a First Class BSc in Genetics from the University of York and PhD in Biochemistry/Molecular Biology from the University of Leicester.

Nick Wright

Chief Executive Officer

Tel: 0116 238 8200

M: 07949 525753


Nick became Chief Executive Officer of Catapult Ventures in September 2013 and oversees the day to day running of the business.

Nick has been managing investment funds since 2003 and has overseen more than 100 transactions. Prior to Catapult he managed an early stage venture capital fund investing in Midlands businesses and prior to that he was Commercial Director of a proof of concept fund set up by Stanford University in California and the University of Edinburgh, where he also founded two MSc entrepreneurship courses.

Nick previously established the technology research team at Fast Track where he launched The Sunday Times Tech Track 100 business supplement. He began his career with Financial Times when he joined and later ran China's first foreign Internet joint venture, before returning to London as a consultant to help FT Group assess their internet strategy in the Far East. He has also had stints with Information Age (bought by Vitesse Media) and internet incubator GorillaPark, headquartered in Amsterdam.

In 2005 Nick co-founded CereProc, now a leading speech synthesis company and he has been an advisor to investment bank GP Bullhound since its inception. He was also an advisor to Scoopt.com, one of the first citizen media companies, from initial trading until acquisition by Getty Images in 2007. Nick has also spent time on the advisory board of UnLtd Ventures, a £100m social entrepreneurship fund financed by the National Lottery.

Nick holds a BSc from the London School of Economics and an Advanced Diploma in Computing from Kellogg College, University of Oxford. He speaks basic Chinese.

From our portfolio

Blueberry Therapeutics


Blueberry Therapeutics is a biotechnology company developing a range of anti-microbial products u...

viewview our portfolio

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200